The immune response is a dynamic multistep process with a complex system regulation. Identification of predictive biomarkers is therefore challenging. Deep investigation of an exceptional responder to pembrolizumab in ovarian cancer identifies a new mechanism of response and highlights the interest of individualized medicine strategy. Clin Cancer Res; 2414; 3233-5. 2018 AACRSee related article by Bellone et al. p. 3282. Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?